Ulrika Segersten1, Yael Spector2, Yaron Goren2, Sarit Tabak2, Per-Uno Malmström3. 1. Department of Surgical Sciences, Uppsala University, Uppsala, Sweden. Electronic address: ulrika.segersten@surgsci.uu.se. 2. Rosetta Genomics Ltd, Rehovot, Israel. 3. Department of Surgical Sciences, Uppsala University, Uppsala, Sweden.
Abstract
OBJECTIVE: To analyze microRNA profile in Ta and T1 urinary bladder cancers in combination and separately and to relate this to the risk of later developing higher-stage disease. MATERIALS AND METHODS: Formalin-fixed, paraffin-embedded samples of 44 Ta and 42 T1 bladder cancers representing cases with and without stage progression during follow-up were collected and microRNA expression levels were measured by microarray analysis. RESULTS: In a comparison between the progressors and controls, in the Ta/T1 group, miR-10a-5p and miR-31-5p were differentially expressed. miR-10a-5p was also correlated to time to progression (P = 0.00012). In the subgroup analysis, 3 microRNAs, miR-10a-5p, miR-31-5p, and miR-130a-3p, were differentially expressed among Ta tumors and had a fold change of more than 1.5 (P<0.038). The comparison concerning microRNA expression between the progressors and controls in category T1 cancers revealed no significant differences. CONCLUSIONS: Profiling revealed that certain microRNAs predicted the risk of developing higher-stage disease among patients with Ta cancers. Lower miR-10a-5p expression in Ta progressing tumors indicates that this microRNA could be important for later malignant potential among this group of patients.
OBJECTIVE: To analyze microRNA profile in Ta and T1 urinary bladder cancers in combination and separately and to relate this to the risk of later developing higher-stage disease. MATERIALS AND METHODS:Formalin-fixed, paraffin-embedded samples of 44 Ta and 42 T1 bladder cancers representing cases with and without stage progression during follow-up were collected and microRNA expression levels were measured by microarray analysis. RESULTS: In a comparison between the progressors and controls, in the Ta/T1 group, miR-10a-5p and miR-31-5p were differentially expressed. miR-10a-5p was also correlated to time to progression (P = 0.00012). In the subgroup analysis, 3 microRNAs, miR-10a-5p, miR-31-5p, and miR-130a-3p, were differentially expressed among Ta tumors and had a fold change of more than 1.5 (P<0.038). The comparison concerning microRNA expression between the progressors and controls in category T1 cancers revealed no significant differences. CONCLUSIONS: Profiling revealed that certain microRNAs predicted the risk of developing higher-stage disease among patients with Ta cancers. Lower miR-10a-5p expression in Ta progressing tumors indicates that this microRNA could be important for later malignant potential among this group of patients.
Authors: Ahmed A Moustafa; Mohammed Ziada; Abubaker Elshaikh; Amrita Datta; Hogyoung Kim; Krzysztof Moroz; Sudesh Srivastav; Raju Thomas; Jonathan L Silberstein; Krishnarao Moparty; Fatma Elzahraa H Salem; Ola H El-Habit; Asim B Abdel-Mageed Journal: Exp Biol Med (Maywood) Date: 2016-12-08